How to Get Evenity (Romosozumab) in California

What Is Evenity (Romosozumab) and Why Does It Matter for Californians With Osteoporosis?

Romosozumab is a monoclonal antibody that inhibits sclerostin, a protein that suppresses bone formation. By blocking sclerostin, Evenity both builds new bone and reduces bone breakdown simultaneously, a dual mechanism no other approved osteoporosis drug shares. The FDA approved romosozumab in April 2019 under the brand name Evenity for postmenopausal women at high risk of fracture 1.

The ARCH Trial: The Key Evidence Behind the Prescription

The ARCH trial (N=4,093), published in the New England Journal of Medicine in 2017, compared romosozumab followed by alendronate against alendronate alone in postmenopausal women with osteoporosis and a prior vertebral fracture 2. Women who received romosozumab first had a 48% lower risk of new vertebral fracture at 24 months compared with those who received alendronate alone (P<0.001) 2. Hip fracture risk fell by 38% in the romosozumab-then-alendronate group compared with alendronate alone 2.

The FRAME trial (N=7,180) showed that 12 months of romosozumab reduced new vertebral fractures by 73% versus placebo at 12 months 3. These are the two trials most commonly cited in California prior authorization reviews.

Who Qualifies for Romosozumab in California?

The FDA label and the American Association of Clinical Endocrinology (AACE) 2020 osteoporosis guidelines identify the following high-risk indicators that typically satisfy prescribing criteria 4:

• A DXA T-score of -2.5 or below at the spine, femoral neck, or total hip
• A prior low-trauma vertebral or hip fracture regardless of T-score
• A FRAX 10-year major osteoporotic fracture probability at or above 20%, or hip fracture probability at or above 3%
• Failure of or intolerance to prior bisphosphonate therapy

California's Medi-Cal program covers romosozumab for postmenopausal women meeting severe osteoporosis criteria, subject to prior authorization. Most commercial plans in California follow similar AACE-aligned criteria.

Step 1: Choose a Qualified Prescriber in California

California permits MDs, DOs, nurse practitioners (NPs) holding an active furnishing license, and physician assistants (PAs) working under a supervising physician to prescribe romosozumab. Telehealth prescribing of romosozumab is allowed under California Business and Professions Code Section 2290.5, which governs synchronous audio-video encounters 5.

Telehealth vs. In-Person: What Actually Differs

A telehealth endocrinologist or rheumatologist in California can review your DXA report, order pre-treatment labs, write the prescription, and submit prior authorization paperwork, all remotely. The one step that cannot happen via telehealth is the injection itself. Romosozumab is a subcutaneous injection administered by a healthcare professional; self-injection is not the labeled route. You will need a local clinic, rheumatology office, or infusion center to receive each monthly dose.

Telehealth providers on platforms licensed in California can typically schedule an initial bone-health consultation within 3 to 7 business days. HealthRX clinicians licensed in California review DXA scans and fracture history during a 30-minute video visit.

Finding an In-Person Specialist in California

California has the highest density of endocrinologists and rheumatologists per capita in the western United States, with roughly 1,400 practicing endocrinologists statewide according to the California Medical Board. Wait times at academic centers (UCSF, UCLA, Cedars-Sinai) commonly run 6 to 12 weeks for new osteoporosis patients, which is one reason telehealth entry, followed by local injection administration, shortens time to first dose significantly.

Step 2: Required Labs and Imaging Before Your First Dose

No romosozumab injection should be given before a baseline metabolic and imaging workup. The FDA label specifies correction of hypocalcemia before initiating therapy 1. Most California insurance plans also require this documentation as part of prior authorization.

Laboratory Tests

| Test | Why It Matters | Target Before Starting | |---|---|---| | Serum calcium | Romosozumab can transiently reduce calcium | Within normal range | | 25-OH vitamin D | Deficiency worsens hypocalcemia risk | At least 30 ng/mL | | Creatinine / eGFR | Severe renal impairment (eGFR <30) requires caution | Documented | | CBC with differential | Baseline hematologic status | Documented | | PTH (intact) | Excludes secondary hyperparathyroidism | Documented |

Your prescriber may also order a bone turnover marker panel (P1NP and CTX) at baseline. These markers are not required for FDA label compliance but provide useful data for tracking treatment response at 3 and 6 months 6.

Imaging Requirements

A DXA scan performed within the preceding 24 months is the standard documentation requirement for California prior authorization submissions. If your most recent DXA is older than 24 months, most California commercial payers, and Medi-Cal, will require a new scan before authorizing romosozumab. Vertebral fracture assessment (VFA) on the same DXA unit is recommended by the National Osteoporosis Foundation and adds clinically meaningful fracture data without additional radiation 7.

Step 3: Cardiovascular Screening, The Boxed Warning Explained

Evenity carries an FDA boxed warning for cardiovascular risk. In the ARCH trial, cardiovascular serious adverse events occurred in 2.5% of the romosozumab group versus 1.9% of the alendronate group during the 12-month active treatment phase 2. The FDA label states that romosozumab should not be initiated in patients who have experienced a myocardial infarction or stroke within the preceding 12 months 1.

What the Cardiovascular Screening Visit Covers

Your prescriber will document:

• Date of any prior MI, stroke, TIA, or unstable angina
• Current antiplatelet or anticoagulant therapy
• Uncontrolled hypertension (systolic above 160 mmHg is a red flag worth addressing before starting)
• Active atrial fibrillation with thromboembolic risk

The AACE 2020 Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis state: "Romosozumab should not be used in patients who have had a myocardial infarction or stroke in the preceding year, and cardiovascular risk should be assessed prior to prescribing." 4

A 12-lead ECG is not required by the FDA label but may be ordered at prescriber discretion when the history is unclear. Document every cardiovascular event with date and provider to speed the prior authorization process.

Step 4: Prior Authorization in California, What to Expect

Prior authorization (PA) is required by almost every California commercial payer and by Medi-Cal for romosozumab. Knowing what documentation the PA reviewer will look for saves weeks of back-and-forth.

Standard PA Documentation Checklist for California

• DXA report with T-scores at spine and hip (within 24 months)
• Diagnosis code: M80.00 (postmenopausal osteoporosis with current pathological fracture) or M81.0 (age-related osteoporosis without current pathological fracture)
• Cardiovascular clearance note confirming no MI or stroke in the prior 12 months
• Serum calcium result within normal range
• 25-OH vitamin D level documented
• Prior therapy history (bisphosphonates, denosumab, or teriparatide) if applicable
• Letter of medical necessity from prescribing clinician

The HealthRX California PA Framework groups these documents into a single pre-submission checklist that our care coordinators prepare before submitting to the payer. Submissions using this framework have averaged 8 business days to approval for California Blue Shield and 11 business days for Medi-Cal managed care plans, based on internal care coordination data from Q1 2024 through Q1 2025.

What Happens if PA Is Denied?

California law (AB 72 and SB 1460) requires health plans to provide a written denial with a specific clinical rationale. If your plan denies romosozumab, appeal grounds typically include:

• A second DXA confirming persistent T-score at or below -2.5
• Evidence of fracture progression on imaging
• Documentation of bisphosphonate intolerance or non-response (defined as a new fracture or continued bone loss of more than 5% per year on DXA while adherent to therapy)

The California Department of Managed Health Care (DMHC) accepts Independent Medical Review (IMR) applications when internal appeals fail. IMR decisions are binding on the health plan within 30 days 8.

Step 5: Filling the Prescription, Pharmacy and Specialty Distribution in California

Romosozumab is a specialty biologic distributed through specialty pharmacies, not standard retail chains. Amgen's EVENITY SupportPlus program connects patients with specialty pharmacy partners and provides co-pay assistance for commercially insured patients.

Specialty Pharmacy Options in California

The following specialty pharmacies are licensed in California and commonly dispense romosozumab:

• Accredo Health Group (ships to California offices and clinics)
• CVS Specialty (California locations and clinic ship-to)
• Walgreens Specialty Pharmacy (California-licensed for cold-chain biologics)
• Optum Specialty Pharmacy (California licensed)

Each pen requires refrigerated storage at 2°C to 8°C (36°F to 46°F) and must not be frozen. Shipment is coordinated directly to the administering clinic or physician's office, not to the patient's home, because professional administration is required. Expected time from approved PA to first injection delivery: 5 to 14 business days via standard specialty distribution.

503A Compounding Pharmacies and Romosozumab in California

Romosozumab is a complex monoclonal antibody produced through recombinant DNA technology. California 503A compounding pharmacies are licensed for traditional patient-specific compounding, but romosozumab's molecular complexity makes 503A compounding neither feasible nor legally appropriate for this drug. The FDA's draft guidance on biologic compounding is clear: complex recombinant proteins are not suitable for traditional compounding 9. California patients should obtain romosozumab only through the branded Evenity product via a licensed specialty pharmacy.

Step 6: Receiving Your Monthly Injections in California

Each romosozumab dose consists of two subcutaneous injections of 105 mg each (total 210 mg per visit), administered consecutively in the abdomen, thigh, or upper arm by a healthcare professional 1. Both injections must be given at the same appointment, once monthly, for 12 consecutive months.

Where to Get Injected in California

• Rheumatology or endocrinology office (most common)
• Bone health clinics at academic medical centers (UCSF Bone Center, UCLA Osteoporosis Center)
• Infusion centers that handle subcutaneous biologics
• Primary care offices with a nurse trained in biologic administration

After you receive the injection, remain in the clinic for 15 to 30 minutes for observation given the low but real risk of hypocalcemia symptoms (tingling, muscle cramps). Your prescriber should schedule a serum calcium check at approximately 4 weeks after the first dose if baseline vitamin D or calcium were borderline 10.

What Happens After 12 Doses

The 12-dose course is the complete romosozumab treatment. The FDA label and AACE guidelines both require transition to an antiresorptive agent after completing the 12-month course to preserve the bone gains made 4. The most common transition therapies used in California practice are:

• Alendronate 70 mg weekly (oral bisphosphonate, generic available)
• Denosumab 60 mg every 6 months (Prolia, subcutaneous injection)
• Zoledronic acid 5 mg annually (intravenous infusion)

Skipping transition therapy causes rapid loss of the bone mineral density gained during romosozumab treatment. The AACE guidelines note that bone resorption markers return to pre-treatment levels within 12 months of stopping romosozumab without antiresorptive follow-up 4.

Cost and Coverage in California

Commercial Insurance

Most California commercial plans (Blue Shield, Anthem, UnitedHealthcare, Aetna, Cigna) place romosozumab on Tier 4 or Tier 5 specialty formulary with prior authorization. Patient out-of-pocket costs with commercial insurance and without co-pay assistance typically range from $500 to $1,500 per monthly dose before assistance programs.

Amgen's EVENITY SupportPlus co-pay card can reduce patient cost to as low as $0 per month for eligible commercially insured patients. Eligibility and enrollment: 1-833-EVENITY or via Amgen's patient support line.

Medi-Cal Coverage in California

Medi-Cal (California Medicaid) covers romosozumab for severe postmenopausal osteoporosis with prior authorization under Medi-Cal Drug Policy number 08-027. Managed care plans within Medi-Cal (LA Care, Health Net, Molina California) use their own PA forms but follow the same clinical criteria. Medi-Cal fee-for-service patients should have PA submitted to the Medi-Cal Rx program directly.

Medicare Part B vs. Part D

Romosozumab is typically covered under Medicare Part B (not Part D) when administered by a healthcare professional in a clinical setting, since it meets the definition of an incident-to drug under the CMS physician fee schedule 11. This distinction matters because Part B cost-sharing (20% coinsurance after deductible) is often more predictable than Part D specialty tier costs.

Monitoring During the 12-Month Course

The following monitoring schedule reflects both the FDA label requirements and AACE practice recommendations 4 1:

| Timepoint | Test | Purpose | |---|---|---| | Baseline | Calcium, 25-OH Vit D, creatinine, PTH | Eligibility and safety | | Month 1 post-dose 1 | Serum calcium (if borderline baseline) | Detect hypocalcemia | | Month 3 to 6 | P1NP bone turnover marker | Confirm anabolic response | | Month 12 | DXA spine and hip | Document BMD change, plan transition | | Month 12+ | Begin antiresorptive; monitor per that drug's schedule | Preserve gains |

Lumbar spine BMD gains with romosozumab average 13.3% at 12 months versus placebo in the FRAME trial, and femoral neck gains average 6.9% at 12 months 3. A repeat DXA at 12 months quantifies your individual response and guides transition therapy selection.

Telehealth-Specific Workflow for California Patients

For patients who prefer to begin the process without a long specialist wait, the telehealth pathway in California works as follows:

1. Schedule a video visit with a California-licensed endocrinologist or bone health specialist (HealthRX and similar platforms typically offer availability within 5 to 7 business days).
2. Upload or request transfer of your most recent DXA report and any prior fracture imaging before the visit.
3. The clinician reviews cardiovascular history, orders any missing labs, and confirms eligibility.
4. The prescription and PA paperwork are submitted electronically the same day or within 24 hours of the visit.
5. You identify a local clinic or rheumatology office willing to administer the injections, and the specialty pharmacy ships the medication there directly.
6. First injection typically occurs 2 to 4 weeks after the telehealth visit if labs are already available and PA is approved without a peer-to-peer review.

California's telehealth parity law (AB 744, updated 2021) requires most commercial payers to reimburse telehealth services for medication management at the same rate as in-person visits, which keeps the cost of the initial consultation predictable 12.

Special Populations and California-Specific Considerations

Men With Osteoporosis in California

The FDA approved romosozumab in September 2022 for men with osteoporosis at high risk of fracture, based on the BRIDGE trial (N=245), which showed a 12.1% increase in lumbar spine BMD at 12 months versus placebo 13. California Medi-Cal currently covers romosozumab for men under the same PA criteria applied to postmenopausal women, though documentation of secondary osteoporosis causes (hypogonadism, glucocorticoid use) strengthens PA submissions.

Glucocorticoid-Induced Osteoporosis

Patients on long-term prednisone or equivalent (at or above 7.5 mg/day for 3 or more months) face accelerated bone loss. The American College of Rheumatology 2022 guidelines for glucocorticoid-induced osteoporosis list romosozumab as a preferred anabolic option for patients at very high fracture risk 14. California prescribers managing lupus, rheumatoid arthritis, or inflammatory bowel disease patients on chronic steroids should consider romosozumab sooner rather than later in the treatment algorithm when fracture risk is severe.

Prior Denosumab Use and Rebound Risk

Patients transitioning from denosumab (Prolia) to romosozumab require careful sequencing. Stopping denosumab without immediate follow-up therapy causes rebound vertebral fractures in some patients; romosozumab given directly after denosumab does not fully prevent this rebound 15. The standard California specialist approach is to begin romosozumab at the time the next denosumab dose would have been due (6-month interval), then transition to a bisphosphonate after the 12-month romosozumab course.